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Abstract
Drug delivery systems inspired by natural particulates hold great promise for targeted cancer 
therapy. Endosome formed by internalization of plasma membrane has massive of membrane 
proteins and receptors on the surface, which is able to specifically target to the homotypic cells. 
Herein, we describe a simple method to fabricate an endosome membrane-coated nanogel (EM-
NG) from source cancer cells. Following intracellular uptake of methacrylated hyaluronic acid (m-
HA) adsorbed SiO2/Fe3O4 nanoparticles encapsulating crosslinker and photoiniator, EM-NG was 
readily prepared through in situ crosslinking initiated under UV irradiation inside endosome. The 
resulting endosome mimetic nanogels loaded with Doxorubicin (DOX) displayed enhanced 
internalization efficiency to the source cells through a specific homotypic affinity in vitro. 
However, when treated the non-source cells, the EM-NGs exhibited insignificant difference in 
therapeutic efficiency compared to bare HA nanogel with DOX. This study illustrates the potential 
of utilizing endosome membrane-mimicking formulation for targeted cancer therapy, and offers 
guideline for developing natural particulates-inspired drug delivery system.
Introduction
Drug delivery systems based on natural particulates have emerged as one of the most 
promising strategies for cancer therapy1. Taking advantages of physical morphologies and 
biological functions of natural particulates, these biomimetic drug delivery carriers offer 
several significant advantages such as selective targeting, prolonged circulation time, and 
low immunogenicity2–6. Among them, natural biological membrane-derived nanoparticles 
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(NPs) have received extensive attention as a simple and viable manner due to their capability 
of mimicking the natural membrane properties. For example, red blood cell membrane-
coated PLGA nanoparticles have shown superior circulation half-life in vivo7–10. In 
addition, it has been validated that cancer cell membrane-coated nanoparticles with full 
array of tumor antigens can promote a tumor-specific immune response and target to the 
source cancer cells via an inherent homotypic binding interaction11. Our previously reported 
work demonstrated that the platelet membrane coated core-shell nanovehicle with 
overexpressed P-Selectin on the membrane could specifically bind to CD44 receptors on the 
surface of cancer cells12.
Endosome plays an important role in regulating fundamental processes in eukaryotic cells, 
such as nutrient uptake, signaling, immunity and adhesion13 The massive amount of 
membrane is internalized into endosome by several endocytic pathways, and the membrane 
lipids and proteins can be recycled back to the plasma membrane in an efficient 
manner13–15. Although precise mechanisms of the recycling and fusion remain to be fully 
elucidated, several previous studies revealed endosome-to-plasma membrane transport is 
mediated with several proteins including Eps15p homology (EH) domains containing 
proteins16, 17. The proteins from the sorting nexin protein family and others can also 
promote the fusion of endosome with the plasma membrane18–21.
In this study, we describe an endosome membrane-coated nanogel (denoted as EM-NG) 
which is easily extracted from the source cancer cells for targeting and specific delivery of 
small molecular drug. As shown in Fig. 1, the EM-NG has an inner core composed of 
hyaluronic acid (HA) nanogel containing SiO2/Fe3O4 nanoparticles, and an endosome 
membrane based outer shell. HA is chosen since it is highly biocompatible and it can target 
to the hyaluronnan receptors CD44, which are overexpressed in a variety of tumor 
types22–26. In order to allow HA nanogel form inside endosome directly, we firstly use core-
shell mesoporous silica NPs with Fe3O4 nanocrystals as the core (SiO2/Fe3O4 NPs) to 
encapsulate crosslinker and photoinitiator, and coat with methacrylated HA (m-HA) on the 
surface through electrostatic interaction. Following the incubation of resulting NPs with 
source cells, an in situ formed nanogel in endosome is obtained by the photo-polymerization 
upon UV light irradiation27–32. The endosome containing HA nanogel is readily collected 
via the magnetic extraction due to the entrapped magnetic Fe3O4 nanocrystals. After loading 
with anticancer drug Doxorubicin (DOX), these EM-NGs can actively target to source 
cancer cells by taking the advantage of the specific interaction with their source cells, and 
subsequently internalize to release DOX.
Experimental
Materials
All chemicals were purchase from Sigma-Aldrich and were used as received. Rhoadmine-
NHS was purchase from Life Technologies (Grand Island, NY, USA).
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Synthesis of Fe3O4 nanocrystals
A solution of 1 M iron (III) chloride hexahydrate and 0.5 M iron (II) chloride tetrahydrate in 
25 mL DI water was added dropwise to a 0.5 M NaOH solution in 250 mL of DI water at 
40°C. The mixture was stirred for 1 h and the nanocrystals subsequently washed with DI 
water until pH neutral. The resulting nanocrystals were dialyzed against DI water for 3 days. 
Finally, the Fe3O4 nanocrystals were stabilized with oleic acid and dispersed in chloroform 
with a concentration of 6.7 mg Fe/mL. The zeta-potential and size distribution were 
measured on the Zetasizer (Nano ZS; Malvern). The TEM images were obtained on a JEOL 
2000FX TEM instrument.
Synthesis of SiO2/Fe3O4 NPs functionalized with quaternary ammonium groups
1 mL of the Fe3O4 nanocrystals in chloroform was poured into 10 mL of 0.55M aqueous 
cethyltrimethylammonium bromide (CTAB) solution and emulsified by sonication for 10 
min. The resulting turbid brown solution was stirred and heated up to 65 °C for 10 min to 
evaporate the chloroform, resulting in a transparent black Fe3O4/CTAB solution. Then, the 
Fe3O4/CTAB solution was added to a mixture of 90 mL of water and 0.6 mL of 2N NaOH 
solution, and the mixture was heated up to 70 °C under stirring. After adding 1 mL of 
tetraethylorthosilicate (TEOS) and 6 mL of ethylacetate, the solution was stirred at 70 °C for 
3 h. Thereafter, the obtained SiO2/Fe3O4 NPs were washed 3 times with ethanol to remove 
the unreacted species and dispersed in 30 mL of ethanol. To extract CTAB, 80 µL of HCl 
was added to the solution and stirred for 3 h at 60 °C. After washing them with ethanol three 
times, the NPs were dispersed in 10 mL of chloroform, and 120 µL of 3-
trimethoxysilylpropyl-N,N,N-trimethylammonium chloride (TMAPS) 50% in methanol was 
added. The reaction solution was stirred at room temperature for 24 h. The resulting SiO2/
Fe3O4 NPs functionalized with quaternary ammonium groups were wash 3 times with 
ethanol and dried in vacuum.
Preparation of HA/SiO2/Fe3O4 NPs
3 mg SiO2/Fe3O4 NPs was mixed with 0.5 mg N,N’-methylenebisacrylamide (MBA) and 
0.1 mg photoinitiator (Irgacure 2959) in PBS buffer for 24 h. Unloaded crosslinker and 
photoinitiator was removed by filtering using a centrifugal filter (100,000 Da molecular 
mass cutoff, Millipore). Then, 1 mg m-HA or rhodamine-HA derivative was added and 
stirred for another 4 h to obtain HA/SiO2/Fe3O4 NPs.
Cell culture
HeLa and A549 cells were obtained from Tissue Culture Facility of UNC Lineberger 
Comprehensive Cancer Center and cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL) and 
streptomycin (100 µg/mL) in a 37°C incubator (Thermal Scientific) under 5% CO2 and 90% 
humidity. The cells were regularly sub-cultured with trypsin-EDTA (0.25%, w/w) and cell 
density was determined with hemocytometer before each experiment.
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Preparation of EM-NG and HA NG
HeLa cells (1×105 cells per well) were seeded in 6-well plates. The cells were allowed to 
culture for 24 h before exposure to the HA/SiO2/Fe3O4 NPs dispersions. The NPs 
dispersions were prepared by diluting the concentrated NPs solution into the FBS free 
medium. The cells were incubated with NPs for 4 h, then the NPs containing medium was 
discarded. After washing the cells by PBS twice, the cells were harvested with trypsin and 
centrifuged at 1000 rpm for 4 min. Then, the cells were resuspended in 1 mL PBS solution 
and exposed to UV irradiation (wavelength: 365 nm) for 1 min to form solid HA nanogel by 
crosslinking polymerization. The cells were lysed with Pierce IP lysis buffer (Thermo 
Scientific). Then, EM-NGs were collected using a magnet from the cells lysate. In order to 
obtain the bare HA nanogel without endosome membrane, the EM-NG were further lysed 
with lysis buffer for a second time, and collected using a magnet.
Intracellular distribution of HA/SiO2/Fe3O4 NPs
HeLa cells (1×105 cells per dish) were seeded in confocal dishes and cultured for 24 h. 
Then, the cells were incubated with rhodamine-HA/SiO2/Fe3O4 NPs for 1h and 4 h. 
Afterward, the cells were washed with PBS twice and stained by LysoTracker green (50 nM) 
(Life Technologies) at 37°C for 30 min. Then, the cells were washed with PBS twice and 
stained with Hoechst 33342 (1µg/mL) for 10 min. After washing with PBS twice, the cells 
were immediately observed using CLSM (LCM 710, Zeiss).
Preparation of DOX-EM-NG
To prepare DOX-EM-NG, 0.03 mL of DOX solution (0.1 mg/mL) was added into 0.27 mL 
of EM-NG solution, and mixed at room temperature for 24 h. Then, the excess DOX was 
remove by filtering using a centrifugal filter (10,000 Da molecular mass cutoff, Millipore). 
The loading capacity (LC) of DOX-EM-NG were determined by measuring the amount of 
encapsulated DOX by analyzing fluorescence intensity of DOX at 590 nm with an excitation 
wavelength of 480 nm using microplate reader (Infinite M200 Pro, Tecan). LC was 
calculated as LC=encapsulated amount of DOX/total weight of DOX-EM-NGs.
Endosome membrane protein characterization
SDS-PAGE was used to separate the proteins contained in the endosome only, EM-NGs and 
NGs. Samples were diluted in protein loading buffer and incubated for 10 min at 100°C. 10 
µL of sample was loaded into each well in a 10% polyacrylamide gel. After separation by 
SDS-PAGE, the proteins were transferred to a nitro cellulose membrane at 300 mA for 3 h 
using a wet transfer method. The membrane was incubated with a 3% BSA blocking 
solution in the PBS TWEEN solution (0.01%) for 30 min at room temperature, and then 
incubated with early endosome antigen 1 (EEA1) in blocking solution overnight at 4°C. 
Afterward, the membrane was washed 3 times with PBS TWEEN 0.01% and incubated with 
the anti-rabbit HRP in blocking solution for 1 h. The membrane was then washed with PBS 
TWEEN 0.01% for 3 times and visualized using a 1-StepTM TMB-Blotting solution 
(Pierce, USA).
Yu et al. Page 4













In vitro DOX release study
The release profile of DOX was measured using dialysis method in PBS buffer. 400 µL of 
DOX-EM-NG solution was added into a dialysis tube (10,000 Da molecular mass cutoff) 
(Slide-A-Lyzer, Thermo Scientific) against 1 mL of PBS buffer solution with different pH 
(7.4 and 5.0). The dialysis tube was incubated at 37°C. At predetermined time intervals, the 
total buffer solution was withdrawn, followed by replacing with fresh buffer solution with 
the same pH. The amount of release DOX was measured through the same method 
mentioned above.
Determination of endocytosis pathways
HeLa cells (1×105 cells per well) were seeded in 6-well plates and cultured for 48 h. 
Afterwards, the cells were pre-incubated with different specific inhibitors for different 
endocytosis pathways, including chlorpromazine (CPZ, 10 µM) for the clathrin-mediated 
endocytosis, nystatin (NYS, 25 µg/mL) for the caveolin-mediated endocytosis inhibition, 
amiloride (AMI, 1 mM) for the macropinocytosis inhibition, and methyl-β-cyclodextrin 
(MCD, 3 mM) for the lipid raft inhibition. Then, the cells were incubated with DOX-EM-
NG at DOX concentration of 1 µM in the presence of the inhibitors for another 2 h. After 
washing the cells by 4°C PBS twice, the fluorescence intensity of DOX in the cells were 
measured by the flow cytometry.
Evaluation of DOX-EM-NG and DOX-NG uptake of HeLa cells
HeLa cells (1×105 cells per well) were seeded in 6-well plates and cultured for 48 h. 
Afterwards, the cells was added with DOX-EM-NGs, DOX-NGs, and free DOX with same 
concentration, and incubated for 2 h. After washing the cells by 4 °C PBS twice, the 
fluorescence intensity of DOX in the cells were measured by the flow cytometry.
In vitro cytotoxicity
HeLa or A549 cells (6×103 cells per well) were seeded in the 96-well plates. After 24 h 
culture, the cells were exposed to EM-NGs, free DOX solution, DOX-EM-NGs and DOX-
NGs with different concentrations of DOX in FBS free medium for 24 h, respectively. Then, 
20 µL per well of MTT solution (5 mg/mL) was added and incubated for another 4 h. After 
removing the medium, 150 µL DMSO was added to each well. The absorbance was 
measured at a test wavelength of 570 nm with a reference wavelength of 630 nm by a 
microplate reader (Infinite M200 PRO, Tecan).
Statistical analysis
All results presented are Mean ± SEM. Statistical analysis was performed using Student’s t-
test or ANOVA test. With a p value < 0.05, the differences between experimental groups and 
control groups were considered statistically significant.
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Preparation and characterization of HA/SiO2/Fe3O4 NPs
Magnetic Fe3O4 nanocrystals was synthesized by a traditional aqueous co-precipitation 
technique33. The obtained Fe3O4 nanocrystals was characterized by dynamic light scattering 
(DLS) and transmission electron microscope (TEM). As shown in Fig. 2a and b, the Fe3O4 
nanocrystals were monodispersed with an average diameter of 22.5 nm. These nanocrystals 
were then coated with mesoporous silica using a sol-gel method34. DLS results revealed that 
the size of SiO2/Fe3O4 NPs increased to 115.3 nm, and the wormhole-like mesopores with a 
size of about 2-3 nm were clearly observed in the silica shells in TEM image (Fig. 2c and d). 
The zeta potential of silica nanoparticles was determined as -30.1±3.3 mV due to surface 
hydroxyl groups.
To adsorb negatively charged m-HA on the surface, 3-trimethoxysilylpropyl-N,N,N-
trimethylammonium chloride (TMAPS) was further functionalized with SiO2/Fe3O4 NPs to 
provide quaternary ammonium groups on the outer surface, which converted the zeta 
potential to 23.2±0.4 mV. After loaded with crosslinker and photoinitiator, m-HA was 
subsequently deposited onto the positively charged SiO2/Fe3O4 NPs by the electrostatic 
assembly. The TEM image clearly showed the HA shell on the surface of SiO2/Fe3O4 NPs 
(Fig. 2e). The negative zeta potential of obtained HA/SiO2/Fe3O4 NPs (-36±1.5 mV) and an 
apparent increase in diameter measured by DLS (Figure 2f) further validated the successful 
coating of m-HA on the surface of SiO2/Fe3O4 NPs.
Preparation and characterization of EM-NGs
To achieve the endosome membrane coating HA nanogels, HA/SiO2/Fe3O4 NPs were first 
required to interact with endosomes. Human cervical carcinoma epithelial (HeLa) cell was 
chosen as a model cell line, and HA/SiO2/Fe3O4 NPs were incubated in the cell culture 
medium with cells. HA/SiO2/Fe3O4 NPs was allowed to internalize the endosome via the 
endo-lysosomal pathway. The successful uptake of HA/SiO2/Fe3O4 NPs in endosome was 
confirmed using the confocal laser scanning microscopy (CLSM). The fluorescence signal 
of the rhodamine tagged HA/SiO2/Fe3O4 NPs was clearly observed in cells after 4 h of 
coincubation, and the fluorescence signals of rhodamine and LysoTracker Green showed 
high colocalization (Fig. 3a), suggesting most of HA/SiO2/Fe3O4 NPs existed in the 
endosomes. After removing the free NPs, the cells were exposed to UV light to initiate the in 
situ photo-polymerization to form the crosslinked HA nanogel in the endosome, namely 
EM-NG. The cells were then lysed, and EM-NG containing magnetic nanoparticle were 
collected via magnetic extraction (Fig. 3d). As determined by DLS, the EM-NG was 262.3 
nm in hydrodynamic diameter (Fig. 3c). The TEM picture showed the EM-NGs were round-
oval in shape, and the membrane with a thickness of 10 nm and the multiple of inclusions of 
silica NPs were clearly observed in each EM-NG (Fig. 3b). To further confirm the successful 
coating of endosome membrane, the western blotting analysis was performed against the 
early endosome antigen 1 (EEA1), the endosome membrane-specific marker. The result 
showed a significant enrichment of EEA1 was present on the EM-NGs rather than the bare 
HA NGs (Fig. 3e).
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Drug loading and release from EM-NGs
DOX, as a model hydrophilic anticancer drug, was loaded into EM-NG via dispersion35,36. 
The loading capacity was determined as 7.3%. The in vitro drug release behavior was 
investigated under different pH conditions over time. The DOX-EM-NG exhibited near a 
zero-order release kinetics at pH 7.4 (Fig. 3f). In contrast, DOX released from nanogel was 
much faster at an acidic condition than physiological condition. The accelerated drug release 
at acidic pH is mainly due to the weakening of the binding between the EM-NG and drug, 
and improved solubility of DOX at low pH37,38. This pH-dependent drug release behavior 
can play a crucial role in tumor-targeted drug delivery via endocytosis pathway.
In vitro delivery of DOX by EM-NG
In order to determine the endocytosis pathway of DOX-EM-NG, HeLa cells were pre-
incubated with several specific inhibitors of different kinds of endocytosis, including 
chlorpromazine (CPZ) for clathrin-mediated endocytosis, nystatin (NYS) for the caveolin-
mediated endocytosis inhibition, amiloride (AMI) for the macropinocytosis inhibition, and 
methyl-β-cyclodextrin (MCD) for the lipid raft inhibition. As shown in Fig. 4b, CPZ, NYS 
and AMI all reduced the uptake of DOX-EM-NG significantly, suggesting that DOX-EM-
NG were taken up by HeLa cells through clathrin-mediated endocytosis, caveolin-mediated 
endocytosis, and lipid raft. In contrast, there was insignificant inhibition of uptake efficiency 
in the cells pretreated with AMI for the macropinocytosis inhibition. These results indicated 
that several pathways were involved in the internalization of cell membrane with DOX-EM-
NG, due to a large number of receptors and proteins on the surface of endosome membrane 
shell of DOX-EM-NG13, 15. The fluorescence of DOX was clearly observed in cells after 1 h 
of incubation with DOX-EM-NG, visualized by CLSM (Fig. 4a and Fig. S1 in the ESI†), 
which validated the cellular internalization of DOX-EM-NG. When prolonged the 
incubation time to 4 h, DOX was remarkably released and delivered into the nuclei of cells. 
To explore the targeting capability of DOX-EM-NG, EM-NG extracted from HeLa cells was 
further lysed to obtain the bare HA nanogel (NG) by removing the endosome membrane39. 
By quantitative analysis using the flow cytometry, it was demonstrated that incubation of 
DOX-EM-NG with HeLa cells in vitro leaded to significantly increased uptake as compared 
to the DOX loaded bare HA nanogel (DOX-NG) and free DOX (Fig. 4c).
In vitro cytotoxicity of DOX-EM-NGs
Next, the in vitro cytotoxicity of nanogel against HeLa cells was evaluated by using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Both DOX-EM-
NG and DOX-NG showed significantly enhanced cytotoxicity toward HeLa cells compared 
to free DOX solution upon 24-hour incubation (Fig. 5a). Notably, the cell viability of cells 
treated with DOX-EM-NG was much lower than that of those treated with DOX-NG, 
suggesting the better cell targeting ability of endosome membrane than the pure HA. The 
results were consistent with the cellular uptake studies measured above. Bare EM-NG did 
not exhibit significant cytotoxicity within the studied range of concentrations. In order to 
assess the capability of DOX-EM-NG to homotypically target cancer cells, the human lung 
adenocarcinoma epithelial (A549) cells, as a heterotypic cell line, were incubated with 
DOX-EM-NG or DOX-NG for 24 h. The results showed there was insignificant difference in 
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cell viability for DOX-EM-NG and DOX-NG (Fig. 5b), which further indicated that the 
enhanced binding effect was specifically associated with the membrane coating.
Conclusions
We have developed an innovative strategy utilizing endosome membrane-coated nanogels 
for enhanced delivery of anticancer drug. HA/SiO2/Fe3O4 NPs encapsulating crosslinker and 
photo-initiator were confirmed to efficiently interact with endosomes by CLSM, and a 
subsequent in situ polymerization happened inside endosome, resulting in the endosome 
membrane coating HA nanogels. These EM-NGs containing magnetic nanocrystals were 
easily collected using a magnet after cell lysis. Through the western blotting analysis against 
endosome membrane specific protein (EEA1), the successful coating of endosome 
membrane was substantiated, and the endosome membrane shell could be removed via 
further lysis for long time. After loading with DOX, the resulting nanogel was demonstrated 
to efficiently target the source cancer cells through a specific homotypic affinity, which 
increased 1.5-fold in uptake efficiency compared to the bare HA NGs. Moreover, DOX-EM-
NGs were able to deliver anticancer drug to source cancer cells with enhanced efficacy, 
while there were insignificant differences compared to DOX-NGs when treated toward non-
source cancer cells.
Furthermore, stimuli-responsive moieties can be integrated with these EM-NGs to achieve 
controllable drug release40. We will also evaluate in vivo targeting capability, antitumor 
efficacy and systemic toxicity of nanogel. This strategy provides guideline to develop 
endosome membrane-coated nanomedicine from primary tumors of patients for personalized 
anticancer treatments.
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Schematic of EM-NG for targeted drug delivery. (a) Preparation of EM-NG from source 
cancer cell. (b) DOX-loaded EM-NGs for targeted drug delivery.
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Characterization of Fe3O4 nanocrystals, SiO2/Fe3O4 NPs and HA/SiO2/Fe3O4 NPs. (a) The 
TEM image and (b) size distribution of Fe3O4 nanocrystals. (Scale bar: 50 nm) (c) The TEM 
image and (d) size distribution of SiO2/Fe3O4 NPs. (Scale bar: 50 nm) (e) The TEM image 
and (f) size distribution of HA/SiO2/Fe3O4 NPs. (Scale bar: 50 nm)
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Characterization of EM-NGs. (a) Intracellular trafficking of rhodamine labelled HA/SiO2/
Fe3O4 NPs on HeLa cell observed by CLSM. The late endo-lysosomes were stained by 
LysoTracker Green, and the nuclei were stained by Hoechst 33342. (Scale bar: 20 µm) (b) 
The TEM image and (c) size distribution of EM-NG. (Scale bar: 200 nm) (d) The 
photograph of EM-NGs collecting by magnetic field. (e) Western blotting analysis of 
endosomes, EM-NGs, and bare NGs against endosome membrane marker: the early 
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endosome antigen 1 (EEA1). (f) DOX release profiles of DOX-EM-NGs at pH 7.4 and 5.0, 
respectively.
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In vitro delivery of DOX by EM-NG. (a) Intracellular trafficking of DOX-EM-NG observed 
by CLSM. The late endo-lysosomes were stained by LysoTracker Green, and the nuclei were 
stained by Hoechst 33342. (Scale bar: 20 µm) (b) Investigation of cellular uptake 
mechanism. Relative uptake efficiency of DOX-EM-NG in the presence of various 
endocytosis inhibitors. Inhibitor of clathrin-mediated endocytosis: chlorpromazine (CPZ, 10 
µM); Inhibitor of caveolin-mediated endocytosis: nystatin (NYS, 25 µg/mL); Inhibitor of 
macropinocytosis: amiloride (AMI, 1 mM); Inhibitor of lipid raft: methyl-β-cyclodextrin 
(MCD, 3 mM). *p <0.05 compared with control group. (c) Relative uptake efficiency of 
DOX-EM-NG, DOX-NG and free DOX on HeLa cells. *p <0.05 for treatment with DOX-
EM-NG compared with DOX-NG and free DOX.
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In vitro cytotoxicity of DOX-EM-NG. (a) In vitro cytotoxicity of EM-NG, free DOX, DOX-
NG and DOX-EM-NG towards HeLa cells after incubation for 24 h. (b) In vitro cytotoxicity 
of free DOX, DOX-NG and DOX-EM-NG towards A549 cells after incubation for 24 h. *p 
<0.05, NS: not significant.
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